exagen-logo-440x386-1.jpg
Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
April 25, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022,...
Practical Cure of Type 1 Diabetes and Autoimmune Diseases by Crowdfunding
Throne Biotechnologies Wins '5 Best BioTech Companies To Watch' Award From The Silicon Review
March 28, 2022 09:00 ET | Throne Biotechnologies Inc
PARAMUS, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Throne Biotechnologies (Throne), one of the global-leading biotech companies aiming to find a cure for type 1 diabetes and other autoimmune...
Exagen logo_440x386 (1).jpg
Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
March 22, 2022 16:06 ET | Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests will soon surpass 90 million lives as...
Exagen logo_440x386 (1).jpg
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
March 22, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
Exagen logo_440x386 (1).jpg
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 22, 2022
March 08, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December...
Fifth Update of ACR
Fifth Update of ACR COVID-19 Vaccine Guidance Supports Fourth Doses for High-Risk Rheumatic Disease Patients
February 02, 2022 10:49 ET | American College of Rheumatology
Atlanta, Feb. 02, 2022 (GLOBE NEWSWIRE) -- The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and...
Exagen logo_440x386 (1).jpg
Exagen Inc. and Queen Mary University of London Announce Exclusive License and Collaboration to Develop Novel Patented Molecular Signatures for Rheumatoid Arthritis Biologic Therapeutic Selection
January 09, 2022 12:00 ET | Exagen Inc.
SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a...
visiongain Logo.png
Autoimmune Disease Therapeutics Market Report Up to 2031: Visiongain Research Inc
December 23, 2021 09:00 ET | Visiongain Ltd
Visiongain has published a new report on Autoimmune Disease Therapeutics Market Report to 2031. Market is segmented By Indication (Rheumatic Disease, Multiple Sclerosis, Diabetes, Inflammatory Bowel...
visiongain Logo.png
Animal Autoimmune Disease Diagnostics Market Report Up to 2031: By Visiongain Research Inc
November 16, 2021 06:13 ET | Visiongain Ltd
Visiongain has published a new report on Animal Autoimmune Disease Diagnostics Market Report to 2031: Forecasts By Test Type (Complete Blood Count, Thyroid Test, Biopsy Test, Urinalysis, DNA...
Graphical Research.jpg
Clinical Trial Market Size & Share 2021 | North America, Europe, & APAC Industry Forecasts 2027: Graphical Research
November 09, 2021 06:00 ET | Graphical Research
Pune, India, Nov. 09, 2021 (GLOBE NEWSWIRE) -- The global clinical trial market size is estimated to rise exponentially during the forecast period, as the need for advanced vaccines and drugs to...